All News

Here’s a preview of the featured content to watch for this week on Drug Topics®.

Here’s a roundup of the latest coronavirus-related news.

Pfizer and BioNTech have initiated rolling submission of their Biologics License Application for full approval of BNT162b2.

Here’s a preview of the featured content to watch for this week on Drug Topics®.

Here’s a roundup of the latest coronavirus-related news.

Flip the Pharmacy announced the winners of its inaugural Flip the Pharmacy Awards.

Here’s a preview of the featured content to watch for this week on Drug Topics®.

A committee of vaccine advisers to the CDC convened to discuss the risk of a rare blood clotting condition linked to the Johnson & Johnson COVID-19 vaccine.

Here’s a roundup of the latest coronavirus-related news.

The European Medicines Agency determined that the benefits of Johnson & Johnson’s COVID-19 vaccine outweigh the risks. The vaccine is still paused in the United States.

Here’s a preview of the featured content to watch for this week on Drug Topics®.

Beginning this week, the OTC self-administered rapid antigen test will be available in Walgreens stores for $23.99.

Here's a roundup of the latest coronavirus-related news.

Here’s a preview of the featured content to watch for this week on Drug Topics®.

Here's the roundup of COVID-19 related news from this week.

What workflow is best for your pharmacy team?

Here’s a preview of the featured content to watch for this week on Drug Topics®.

Pharma Logistics announced it has secured the Pharmaceutical Reverse Distribution Program with the Department of Defense.

Here’s a roundup of the latest coronavirus-related news.

How can pharmacies adapt to patients’ changing needs and embrace this evolution of care moving forward?

Here’s a preview of the featured content to watch for this week on Drug Topics®.

Here’s a roundup of the latest coronavirus-related news.

NCPA applauded the Michigan’s House passage of the legislation, which would reform many PBM reimbursement practices in the state.

The updated analyses of the AZD1222 COVID-19 vaccine will be submitted to the FDA for emergency use authorization, according to AstraZeneca.

AstraZeneca is preparing to submit its COVID-19 vaccine data to the FDA for emergency use authorization in the coming weeks.

The CDC reported data demonstrating high adherence to COVID-19 vaccine doses among recipients.

Here’s a preview of the featured content to watch for this week on Drug Topics®.

Here’s a roundup of the latest coronavirus-related news.